Analysts are positive on these five top "strong buy" dividend stocks for this year. They make sense for growth and income ...

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

The article " Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns " first appeared on MarketBeat.

According to Report Ocean, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~$% between 2022-2028 owing to rise in cases of UTIs, technological advancements ...

Here are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...

We recently compiled a list of the 10 Best January Dividend Stocks To Buy. In this article, we are going to take a look at ...

Cambridge: Atavistik Bio, a biotechnology company has announced that it has entered into a research collaboration with Pfizer ...

Dividend stocks are a favorite among investors for good reason. They provide a steady income stream of passive income and ...

Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...

The FDA had approved Tagrisso for a similar use in September. FDA Approves Pfizer’s Braftovi for First-Line Colorectal Cancer The FDA approved Pfizer’s Braftovi in combination with Erbitux ...

NEW YORK, December 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ...